Last Updated on October 11, 2024 by The Health Master
Zudus
Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to market Bortezomib for injection, 3.5 mg/vial, single-dose vial, a company statement notified.
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.
The medication works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira, the statement added.
Aurobindo
Aurobindo Pharma on Tuesday said its wholly-owned arm Eugia Pharma Specialties Ltd has received final approval from the US health regulator to manufacture and market its generic version of Bortezomib for injection used to treat certain types of cancer.
The approval by the US Food and Drug Administration (USFDA) is for single-dose vial of Bortezomib for injection of strength 3.5 mg/vial, Aurobindo Pharma said in a regulatory filing. The product is the generic version of reference listed drug Velcade of Takeda Pharmaceuticals USA Inc.
The product is being launched immediately, it added.
Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and is also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes), the company said.
The approved product has a market size of USD 1.172 billion for the 12 months ended March 2022, the company said citing IQVIA data.
USFDA grants approval for drug to treat spondylitis
USFDA approves this oral heart disease drug
USFDA gives tentative nod to Alembic Pharma for Ivabradine tablets
USFDA gives nod to Lupin for Desvenlafaxine ER tablets
USFDA authorises first C-19 diagnostic test using breath samples
USFDA gives approval to Aleor for Lidocaine & Prilocaine cream
USFDA grants approval for drug to treat spondylitis
A smarter way to develop new drugs
DCGI extends timeline for Pharma Firms to regularize 294 FDCs
Medical Degrees from Pakistan declared invalid by NMC
Himachal Pharma firms battle higher input costs
Medical Degrees from Pakistan declared invalid by NMC
USFDA approves this oral heart disease drug
E-Pharmacy market in India to grow at 45% in future: Report
Drug alert: 48 out of 1454 samples declared as NSQ in March 2022
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
